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        Bacteria have a remarkable capacity to respond to 
new environments and adapt to novel selective 
pressures. This versatility refl  ects their genetic 
diversity, which is generated by high mutation 
rates, the acquisition of novel sequences by hori-
zontal transfer, and mobile elements and repeated 
sequences in their genomes (  1  ). Consequently, 
populations of bacteria often harbor variants that 
may have a selective advantage in a new or chang-
ing environment. The diversity of bacteria and 
their ability to generate novel variants can pro-
mote their virulence and limit the success of 
prophylactic and therapeutic interventions. 
    Neisseria meningitidis   is a Gram-negative dip-
lococcus that remains a leading cause of bacte-
rial meningitis and septicaemia. The complement 
system is critical for immunity against this im-
portant pathogen, as indicated by the exquisite 
sensitivity of individuals with complement defi  -
ciencies to meningococcal infection (  2  ). This is 
particularly true for people lacking components 
(C5 to C9, inclusive) of the membrane attack 
complex (MAC), which is necessary for bacterial 
lysis (  3  ). Furthermore, the most validated cor-
relate of protection against meningococcal in-
fection is the presence in serum of bactericidal 
antibodies (  4  –  6  ). These antibodies initiate the 
classical pathway (CP) of complement activation, 
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  The presence of serum bactericidal antibodies is a proven correlate of protection against 
systemic infection with the important human pathogen   Neisseria meningitidis.   We have 
identifi  ed three serogroup C   N. meningitidis   (MenC) isolates recovered from patients with 
invasive meningococcal disease that resist killing by bactericidal antibodies induced by the 
MenC conjugate vaccine. None of the patients had received the vaccine, which has been 
successfully introduced in countries in North America and Europe. The increased resistance 
was not caused by changes either in lipopolysaccharide sialylation or acetylation of the 
    2-9  –  linked polysialic acid capsule. Instead, the resistance of the isolates resulted from 
the presence of an insertion sequence, IS  1301  , in the intergenic region (IGR) between the 
  sia   and   ctr   operons, which are necessary for capsule biosynthesis and export, respectively. 
The insertion sequence led to an increase in the transcript levels of surrounding genes and 
the amount of capsule expressed by the strains. The increased amount of capsule was 
associated with down-regulation of the alternative pathway of complement activation, 
providing a generic mechanism by which the bacterium protects itself against bactericidal 
antibodies. The strains with IS  1301   in the IGR avoided complement-mediated lysis in the 
presence of bactericidal antibodies directed at the outer membrane protein, PorA, or raised 
against whole cells. 1424 INCREASED COMPLEMENT RESISTANCE IN   N. MENINGITIDIS   | Uria et al.
identifi  ed, against which the SBA titers of sera from all three 
vaccinees was   <  8. The strains were tested with sera from 
fi  ve more vaccinees with identical results. SBA titers against 
MenC are routinely measured with rabbit complement (  6, 
14  ); similar results were obtained when assays were performed 
with human complement (Table S1, available at http://www
.jem.org/cgi/content/full/jem.20072577/DC1). Isolate R1 
was recovered from a 37-yr-old female with fatal meningo-
coccal septicaemia in Madrid in 2000, whereas R2 was ob-
tained from blood cultures taken from a 40-yr-old female 
from L  é  on in 2003. R3 was isolated from blood cultures 
from a 19-yr-old female in Valladolid in the same year. 
None of the patients had received a MenC vaccine, and the 
patients infected with strains R2 and R3 made uneventful 
recoveries. The R strains were phenotypically C:2a:P1.5 
and ST-11, subgroup ET-15 (ST-11/ET-15) by multilocus 
sequencing typing and   fumC   sequencing (  20  ). Five fully sen-
sitive C:2a:P1.5, ST-11/ET-15 isolates (designated S1  –  S5) 
were selected from the collection at the reference laboratory 
ultimately leading to the insertion of the MAC into the outer 
membrane of   N. meningitidis   and bacteriolysis. 
  The   N. meningitidis   serogroup C conjugate (MCC) vaccine 
has been recently introduced into countries across Europe 
and North America (  7, 8  ), primarily in response to the rising 
incidence of serogroup C   N. meningitidis   (MenC) disease 
caused by strains belonging to sequence type 11 (ST-11) (  9  ). 
ST-11 strains have been responsible for meningococcal in-
fection across the world, causing endemic disease usually as 
MenC isolates and occasional outbreaks as serogroup W135 
isolates (  10  –  12  ). The MCC vaccine consists of the     2-9  –
  linked polysialic capsular polysaccharide coupled to a carrier 
protein (  13  ), and protection is mediated by bactericidal anti-
bodies directed against the capsule (  4, 6  ). The level of these 
antibodies in individuals is measured by the serum bacteri-
cidal antibody (SBA) assay, and an SBA titer of   ≥  8 is a proven 
correlate of protection against MenC disease (  4, 14  ). 
  The MCC vaccine has been a major success and has re-
sulted in dramatic decreases in the incidence of MenC disease 
to   <  5% of prevaccine levels, with an estimated vaccine effi   cacy 
between 95  –  98% (  7, 8, 15  ). So far, concerns (  16  ) that the 
MCC vaccine would lead to the emergence of ST-11 strains 
expressing other capsular types or that other strains of   N. 
meningitidis   would fi  ll the ecological niche vacated by MenC 
have proven largely unfounded, although continuing surveil-
lance is still underway (  8  ). 
  In this study, we describe the identifi  cation and charac-
terization of three MenC strains with enhanced resistance 
against bactericidal antibodies elicited by the MCC vaccine. 
We found that an insertion sequence, IS  1301  , in the 134-bp 
intergenic region (IGR) between the   sia   and   ctr   operons (in-
volved in capsule biosynthesis and export, respectively) is 
responsible for the resistance. Previously, IS  1301   has only been 
described as causing gene inactivation in   N. meningitidis   (  17  ). 
Insertion of this element in the IGR results in increased tran-
script levels in both operons, leading to an increase in the 
amount of capsular polysaccharide and impairment of the al-
ternative pathway (AP) of complement activation. This single 
genetic change provides the meningococcus with a generic 
mechanism to evade killing by bactericidal antibodies, and is 
of broad signifi  cance given the widespread distribution of 
IS  1301   in   N. meningitidis   and the bacterium  ’  s competence 
for DNA uptake. 
    RESULTS   
  Identifi  cation of MenC strains that avoid bactericidal 
antibodies elicited by the MCC vaccine 
  To identify meningococcal strains that are resistant to SBAs 
raised by the MCC vaccine, we used sera from three vacci-
nees to screen 109 MenC isolates from patients with proven 
meningococcal disease received by the Spanish National 
Reference laboratory between 2000 and 2003. The three 
vaccinees had been immunized with an MCC vaccine and 
had high level SBA titers against C11, a MenC strain rou-
tinely used for assessment of vaccine responses (  Fig. 1 A  ) 
(  18, 19  ).   Three strains, designated R1, R2, and R3, were 
    Figure 1.         Identifi  cation of strains with increased resistance 
against bactericidal antibodies elicited by the MenC conjugate 
vaccine.   (A) SBA titers using sera from eight vaccinees against the R strains 
and the control strain, C11. All sera had SBA titers of   <  8 with the R strains. 
(B) The percent survival of strains S3, S4, and R3 after 1 h of incubation in 
dilutions of human immune serum. Assays were performed in triplicate, 
and the error bars show the SEM. The survival of R3 was signifi  cantly 
increased compared with other strains. P = 0.0002 and 0.0001 at a 1:2 
and 1:4 serum dilution, respectively, with the Student  ’  s   t   test.   JEM VOL. 205, June 9, 2008 
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  Strains are not resistant because of changes in LPS 
sialylation or acetylation of capsular polysaccharide 
  To understand the basis of the increased resistance of the R 
strains against immune sera, we fi  rst examined the degree of 
LPS sialylation of strains, as this modifi  cation can contribute 
to the avoidance of complement-mediated lysis (  3, 21  ). There 
were no consistent diff  erences in the degree of LPS sialylation 
between the R and S strains, as determined by Western blot 
analysis using mAb 3F11, which binds to unsialylated LPS 
(  Fig. 2 A  ) (  22  ).   To exclude the possibility that LPS sialylation 
was responsible for the resistance of strains, we inactivated   lst   
(which encodes the LPS-specifi  c sialyl transferase) in strain 
R3. This had no impact on the survival of this strain in the 
presence of immune sera, demonstrating that its resistance is 
independent of LPS sialylation (  Fig. 2 B  ). 
  We next examined whether alterations in the acetylation 
status of the capsule aff  ected the resistance of strains. Capsule 
  O  -acetylation is mediated by a transferase encoded by   oatC  , 
which is located in the capsule biosynthesis locus (  cps  ) (  23  ). 
The   oatC   open reading frame contains two homopolymeric 
tracts that can mediate ON:OFF switching of acetylation af-
ter alteration in the tract length during DNA replication (  23  ). 
The nucleotide sequence of the   oatC   gene in the R and S 
strains indicated that the gene is predicted to be expressed in 
all strains (unpublished data). The capsules of all strains were 
acetylated, as demonstrated by FACS analysis using the mAb 
1125 (  Fig. 2, C and D  ). To defi  ne the role of   O  -acetylation in 
the behavior of the R strains, we generated an   oatC   mutant, 
R3::  oatC  , by insertional inactivation. Loss of   oatC   did not al-
ter the survival of this strain in the presence of immune sera 
(  Fig. 2 E  ), excluding acetylation as the cause of the diff  erence 
between the R and S strains. 
  Insertion of IS  1301   in the capsule biosynthesis locus 
is responsible for increased resistance 
  To investigate the role of the capsule itself, we generated 
capsule-negative derivatives of strains R3 and S3 by inacti-
vating   siaD  , which encodes the capsule-specifi  c  polysialyl 
transferase (  24  ). Although the SBA titer of the vaccinees  ’   sera 
(which contain antibodies against subcapsular antigens as well 
as against capsular polysaccharide) against strain S3 was largely 
unchanged after loss of the capsule, R3 became markedly 
more susceptible to killing (  Fig. 3 A  ), with the SBA titer in-
creasing from   <  8 for R3 to   ≥  512 for R3      siaD  .   This demon-
strates that expression of the capsule is necessary for the 
enhanced resistance of R3, suggesting that the R strains might 
harbor changes in the   cps   that mediate their enhanced survival 
in the presence of immune sera. To test this hypothesis, we 
attempted to transfer the resistance from an R strain with 
a marker in the   cps   into a sensitive strain. Genomic DNA 
from strain R3::  oatC   (  Fig. 3 B  ) was used to transform S3, and 
kanamycin-resistant transformants were analyzed for their 
sensitivity to bactericidal antibodies. As expected (depending 
on whether recombination transferred in sequences responsible 
for increased resistance;   Fig. 3 B  ), we identifi  ed transform-
ants that had become resistant to killing (S3::T1) to antibodies 
as controls. We also examined the recovery of one of the R 
strains after incubation in immune sera, which includes hu-
man complement; R3 was relatively more resistant against 
killing in human immune sera than the control strains, S3 
and S4 (  Fig. 1 B  ). 
    Figure 2.         Resistance of strains is not due to changes in LPS si-
alylation or   O  -acetylation of capsular polysaccharide.   (A) The extent 
of LPS sialylation of the R and S strains. Samples were separated by SDS-
PAGE and transferred to membranes that were then incubated with the 
mAb 3F11, which detects unsialylated LPS. The strains are indicated above 
each lane. (B) SBA titers of two vaccinees  ’   sera against R3, S3, and the 
corresponding   lst   mutants, which are unable to sialylate their LPS; a lack 
of LPS sialylation did not affect the survival of the R or S strains. Both the 
S (C) and R (D) strains express an   O  -acetylated polysaccharide capsule. 
FACS analysis of strains was performed with the mAb 1125. The gray line 
shows results obtained with the   oatC-  negative mutant, R3::  oatC  . (E) The 
sensitivity of S3 and R3 to antibodies in sera from two vaccinees is unaf-
fected by acetylation. Identical SBA titers were obtained with wild-type 
strains and their corresponding   oatC   mutants.   1426 INCREASED COMPLEMENT RESISTANCE IN   N. MENINGITIDIS   | Uria et al.
yielded a signifi  cantly larger product from the transformant 
with enhanced resistance (S3::T1) compared with the fully 
sensitive transformants (S3::T2 and S3::T3;   Fig. 3 C  ). Further 
PCRs were performed to defi  ne the precise location of this 
polymorphic region; using primers NG732 and NG733 (  Fig. 3  ), 
an     1.1-kb fragment was amplifi  ed from S3::T1, whereas an 
elicited by the MCC vaccine, as well as those that remained 
fully sensitive (S3::T2 and S3::T3). 
  To identify regions of the   cps   that might confer the in-
creased resistance, we amplifi  ed overlapping fragments of the 
  cps   from the transformants S3::T1, S3::T2, and S::T3. One 
region of the   cps   (amplifi  ed with primers NG638 and NG639) 
    Figure 3.         Insertion of IS  1301   between the   sia   and   ctr   operons leads to enhanced resistance.   (A) The increased resistance of R3 requires expres-
sion of the polysaccharide capsule. The   siaD   mutant of R3 is sensitive to killing mediated by sera from two vaccinees, compared with the parental strain. 
(B) Transfer of resistance from strain R3 to S3 using genomic DNA from R3::  oatC   as the donor. This was performed to test the hypothesis that R3 (DNA 
shown as a continuous red line) has a region (indicated with a black square) in the   cps   that confers resistance and is different from the S strains (DNA 
shown as a blue dotted line). Transformants have enhanced resistance (S3::T1) or are fully sensitive (S3::T2 and S3::T3) transformants after transformation 
of S3, as would be expected depending on the site of recombination. (C) Overlapping PCR products spanning the   cps   were  amplifi  ed from the transfor-
mants. The strain used as the target is indicated above each lane, and primers are given underneath; the sizes of a kb ladder are shown. White lines indi-
cate that intervening lanes have been spliced out. (D) Analysis of PCR products obtained with primers NG732 and NG733 from the R and S strains. The R 
strains gave a product of around 1.1 kb,     800 bp larger than that obtained from the sensitive strains. (E) Location of the IS  1301   in the 134-bp   siaA-ctrA  
intergenic region (thick black line). which contains a divergent promoter. Transfer of an IGR containing IS  1301   (amplifi  ed with primers NG679 and NG687) 
to S3 (resulting in S3::R) is suffi  cient to confer resistance against killing mediated by bactericidal antibodies in vaccinees  ’   sera. The location of the kan 
resistance marker in strains R3::IS  1301  kan   and S3::R is indicated with a triangle.     JEM VOL. 205, June 9, 2008 
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strains  ’   increased resistance was not caused by an alteration in 
the nature of antigens expressed by the strains. 
  To establish whether there are qualitative changes in the 
capsule from the R strains, we assessed the composition of 
the capsular polysaccharide of strains by   1  H NMR spectros-
copy (  29  ). The one-dimensional NMR spectrum of the se-
rogroup C polysaccharide is sensitive to   O  -acetylation at C7 
or C8, and the local sequence of   O  -acetylated monosaccha-
ride residues (  29  ). The spectrum of purifi  ed capsule from S3 
(  Fig. 4 A  ) was similar to that obtained for R3 and S3::R (  Fig. 
4 B   and not depicted), and this was confi  rmed by two-
dimensional total correlated spectroscopy (not depicted).   This 
demonstrated that the capsular polysaccharides of the strains 
had identical linkages between the sialic acid monomers and 
the same distribution of   O  -acetylation. Therefore, insertion 
of IS  1301   in the IGR did not result in a detectable change in 
the composition of the capsule. 
  We next examined whether insertion of IS  1301   in the 
IGR aff  ected the amount of capsule expressed by infl  uencing 
the expression of neighboring genes. We performed quanti-
tative real-time RT-PCR (qrtRT-PCR) on   siaA   and   ctrA  , 
and compared the results with the transcript levels of a house-
keeping gene,   gdh   (  30  ). Although the transcript levels of   gdh   
were not signifi  cantly diff  erent between the sensitive strains 
and those with enhanced resistance (not depicted), R3 and 
S3::R had a two- to threefold increase in mRNA of both 
  siaA   and   ctrA   compared with S3 (P   <   0.005 for   siaA   and   ctrA   
in R3 and S3::R vs. S3 using the Student  ’  s   t   test;   Fig. 5, A 
and B  , respectively).   We then determined whether the in-
crease in the transcription of genes in the   cps   resulted in an 
    300-bp product was obtained from S3::T2 and S3::T3 
(not depicted). We also examined the sizes of fragments 
obtained with these primers from the isolates R1  –  R3 and 
S1  –  S5, and 27 more fully sensitive, ST-11 strains from the 
Spanish collection. The R strains all gave the larger     1.1-kb 
product, whereas the     300-bp product was amplifi  ed from 
all sensitive strains, demonstrating a direct correlation be-
tween the size of this region of the   cps   and the ability of strains 
to withstand SBAs elicited by immunization with the MCC 
vaccine (  Fig. 3 D   and not depicted). 
  Sequence analysis demonstrated that the polymorphism 
in the   cps   locus resulted from the presence of an insertion se-
quence, IS  1301  , in the 134-bp IGR between   siaA   and   ctrA   in 
all R strains and S3::T1.   siaA   and   ctrA   are the fi  rst genes in 
monocistronic operons involved in the biosynthesis and ex-
port of capsular polysaccharide, respectively. The operons are 
divergently transcribed from promoters in the IGR (  25  –  27  ). 
IS  1301   is an 844-bp mobile element that is present in multi-
ple copies in the genomes of some meningococcal strains, 
including ST-11 isolates belonging to ET-15 (  17, 28  ). The 
insertion sequence was located at the identical site in the same 
orientation in all three R strains, 54 bp upstream of the ATG 
start codon of   siaA  . To establish whether IS  1301   in the   siaA  -  ctrA   
IGR is responsible for the resistance of the R strains, we 
transferred this element from R3 into the sensitive strain, S3. 
First, a marker encoding kanamycin resistance was introduced 
into nucleotide 472 of IS 1301   in R3, generating R3::IS 1301    kan  ; 
the marker had no eff  ect on the SBA of pooled immune sera 
against R3 (  Fig. 3 E  ). Then, we transferred the only modifi  ed 
IGR into S3, generating the isogenic strain S3::R, and this 
was suffi   cient to transfer increased resistance against bacteri-
cidal antibodies to strain S3 (  Fig. 3 E  ). 
  Insertion of IS  1301   in the IGR increases capsule expression 
but does not affect its structure 
  We next determined whether the insertion of IS  1301   af-
fected the antigenic properties of the capsular polysaccharide. 
Initially immune sera were raised against the isogenic strains, 
S3 and S3::R, and against R3. As expected, sera raised against 
S3 mediated killing of the homologous strain S3 (SBA titer 
1,024) but not S3::R or R3 (  Table I  ).   High dilutions of sera 
raised against S3::R and R3 were also able to elicit comple-
ment-mediated lysis of S3, consistent with the capsular poly-
saccharide from the R strains retaining its immunogenicity. 
However, even high concentrations of the same sera failed to 
mediate killing of S3::R or R3 (  Table I  ), suggesting that the 
    Table I.        SBA titers of sera raised against different strains in 
assays against homologous or heterologous strains 
SBA titer against
Sera raised versus S3 S3::R R3
S3 1,024   <  8  <  8
SR 1,024   <  8  <  8
R3 1,024   <  8  <  8
    Figure 4.           1  H NMR spectra of purifi  ed capsular polysaccharide.   No 
signifi  cant difference was identifi  ed between the capsules from strains S3 
(A) and R3 (B). The asterisk denotes the internal standard (acetone), and 
the prominent and distorted peaks at     4.8 parts per million (ppm) in 
both spectra are caused by partially deuterated water.     1428 INCREASED COMPLEMENT RESISTANCE IN   N. MENINGITIDIS   | Uria et al.
and viewed by TEM without sectioning. With this method, 
capsular polysaccharide was clearly visualized around strain 
S3 (  Fig. 6, A and B  ); no staining was detected around the 
  siaD   mutant (  Fig. 6, C and D  ), demonstrating the specifi  city 
of staining.   In contrast, there was much more capsule sur-
rounding R3 and S3::R than observed around S3 (  Fig. 6, E 
and F; and G and H  , respectively), with capsular material 
extending well beyond the bacterial surface occasionally as 
aggregates of extracellular material. The diff  erences between 
the strains were consistent on three independent occasions. 
  Activation of the alternative complement pathway 
is reduced on the strains with enhanced resistance 
  An increase in the expression of capsule, the antigen recog-
nized by SBAs elicited by the MCC vaccine, could enhance 
the sensitivity of strains to immune sera rather than render 
them more resistant. Therefore, to further understand the 
underlying reason for the resistance of the strains, we exam-
ined the deposition of complement factors on bacteria after 
incubation in immune sera. Both R3 and S3::R had signifi  cantly 
increase in the amount of the SiaA protein that is encoded by 
the fi  rst gene of the   sia   operon. Western blot analysis with an 
antipeptide antibody demonstrated that R3 and S3::R pro-
duced higher levels of SiaA than strain S3 (  Fig. 5 C  ). We also 
determined the amount of capsular polysaccharide on the surface 
of the bacteria. We performed FACS analysis using polyclonal 
mouse sera raised against the MCC vaccine. Examination of 
a strain lacking capsule R3      siaD   demonstrated that there was no 
nonspecifi  c binding of the antisera to   N. meningitidis   (  Fig. 5 D  ). 
There was a signifi  cant increase in capsule expression by strains 
R3 and S3::R when compared with S3 (P   <   0.005 for both 
strains with increased resistance vs. S3 using the Student  ’  s   t   test; 
  Fig. 5, D and E  ); the mean fl  uorescence index (MFI) of the 
strains with enhanced resistance was approximately three times 
higher when compared with the sensitive S3 strain. 
  Furthermore, we examined the strains by cryo  –  transmis-
sion electron microscopy (cryo-TEM) after labeling live bac-
teria with the electron-dense, cationic stain ferritin, which 
binds to negatively charged bacterial capsules (  31  ). After in-
cubation with ferritin, bacteria were fi  xed by rapid freezing 
    Figure 5.         Insertion of IS  1301   increases the levels of   siaA   and   ctrA   transcripts and the amount of polysaccharide capsule expressed by bacteria.  
The relative amounts of   siaA   (A) and   ctrA   (B) transcripts from S3, R3, and S3::R measured by qrtRT-PCR. Error bars show the SEM of assays performed in 
triplicate. P   <   0.005 for differences in   siaA   and   ctrA   mRNA levels in R3 and S3::R versus S3 using the Student  ’  s   t   test. (C) Western blot analysis of SiaA and 
RecA in whole-cell lysates. The strains are indicated above each lane, and the sizes of the proteins (in kD) are shown. (D) Expression of the polysialic capsule 
detected by FACS. Bacteria were incubated with polyclonal antisera raised against the MCC vaccine (black, capsule-negative strain R3    siaD  ; blue, S3; red, 
S3::R; purple, R3). (E) Relative amount of capsule detected by FACS. Results are shown as the MFI (calculated as the geometric mean multiplied by the 
percentage of positive cells). Error bars show the SEM. P   <   0.005 for both strains with increased resistance versus S3 using the  Student ’ s   t   test.   JEM VOL. 205, June 9, 2008 
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incubation in immune sera by blocking the CP and lectin 
pathway (LP) with magnesium and EGTA (  36, 37  ). As ex-
pected, this resulted in signifi  cantly lower overall levels of 
complement factors deposited on the bacteria. However, 
there was still signifi  cantly less C3 and MAC present on R3 
and S3::R than S3 even in the absence of the CP and LP 
(P   <   0.01;   Fig. 7, C and D  , respectively), demonstrating that 
strains with enhanced resistance had reduced activity of the 
AP on their surface. 
less C3 and MAC on their surfaces compared with the fully 
sensitive strain S3 (  Fig. 7, A and B  , respectively), consistent 
with the results of SBA titers and serum assays (  Fig. 1  ).   Sialic 
acid  –  containing capsules can inhibit the amplifi  cation of the 
complement cascade by interfering with the AP of comple-
ment activation ( 32  –  34  ); the AP serves to amplify the amount 
of complement activation on pathogen surfaces (  35  ). There-
fore, we examined whether there were diff  erences in the 
extent of the AP activity on the surface of the strains after 
    Figure 6.         Ferritin staining of capsular polysaccharide detected by cryo-TEM.   Capsular material was detected around the surface of the sensitive 
strain S3 (A and B, arrows) but not the corresponding   siaD   mutant (C and D). Strains R3 and S3::R (E and F; and G and H, respectively) expressed larger 
amounts of capsule, which formed large extracellular aggregates in places. Bars, 400 nm.     1430 INCREASED COMPLEMENT RESISTANCE IN   N. MENINGITIDIS   | Uria et al.
  In contrast, our data demonstrate that insertion of IS  1301   
in the   sia  -  ctr   IGR actually leads to an increase in the amount 
of the target antigen on the bacterial surface. However, the 
capsule is not only the target of the immune response but is 
also an important means by which bacteria are protected against 
complement-mediated killing. The reduced level of C3 bound 
to the strains with increased resistance in the absence of the 
CP and LP is in keeping with their enhanced resistance re-
sulting from inhibition of the AP associated with increased 
capsule expression (  32  –  34  ). The function of the AP is to am-
plify complement activation initiated by the CP and LP, or 
the spontaneous low level generation of C3b from C3 in the 
circulation (  35  ). Therefore, inhibition of the AP reduces com-
plement activation regardless of the initial stimulus. However, 
other mechanisms could also contribute, including elevated 
turnover and shedding of capsular antigen by the R strains 
(directing SBAs away from the bacterial surface). Furthermore, 
the enhanced capsule could also directly inhibit insertion of 
the MAC (a large multiprotein complex of around 1 mD) into 
the outer membrane, thereby preventing bacterial lysis (  35, 43  ). 
Masking of subcapsular antigens might promote resistance 
against killing mediated by     -PorA mAbs and antibodies raised 
against whole cells. 
  This is the fi  rst time that IS  1301   has been shown to in-
crease gene expression in the meningococcus, although it has 
been described before in   Actinobacillus actinomycetemcomitans   (  44  ). 
Instead, this element has been associated with reversible in-
activation of genes, including   porA  ,   siaA  , and   oatC   (  23, 45, 46  ). 
ST-11/ET-15 isolates, which contain between 15 and 20 cop-
ies of IS  1301   (  17  ), have caused outbreaks of meningococcal 
disease with high case fatality rates (  47, 48  ). Although it is not 
known whether these strains are inherently more virulent, 
IS  1301   could have a signifi  cant impact on the pathogenesis 
of ET-15 infections by up-regulating expression of specifi  c 
  If the increased amount of capsular polysaccharide inhibits 
the AP, this could provide a generic mechanism that protects 
the bacterium against bactericidal antibodies irrespective of 
the target antigen. We therefore tested the sensitivity of strains 
against an mAb against PorA (P1.5), an immunogenic outer 
membrane protein that elicits bactericidal antibodies (  38  ). 
Although the mAb mediated lysis of the S strains with titers of 
128 or 256, the titer against the R strains was   <  8; these fi  ndings 
were confi  rmed in assays using a human complement source 
(Table S1) and are consistent with the lack of killing in the 
presence of antibodies raised against whole cells (  Table I  ). 
    DISCUSSION   
  We have identifi  ed MenC strains that have increased resis-
tance against complement-mediated bacterial lysis, the most 
critical aspect of immunity against   N. meningitidis  . The strains 
belong to the ST-11 clone, which has spread across the world 
since fi  rst emerging in Canada (  10, 12  ). The strains contain the 
identical genetic change in the   cps  , with IS  1301   inserted at 
the same site in the IGR between operons necessary for sialic 
acid biosynthesis and capsule export. None of the sensitive 
strains had this genetic change, and transfer of IS  1301   into the 
IGR of an S strain was suffi   cient to render it resistant to SBAs 
directed against the capsule, the outer membrane protein, PorA, 
and against whole cells. 
  There are numerous instances of bacteria avoiding im-
mune killing through antigenic variation or by reducing ex-
pression of antigens on their surface. These mechanisms have 
been described for PorA, the major immunogen in outer mem-
brane vesicle vaccines (  39  ). A single amino acid change in this 
protein can aff  ect the activity of bactericidal antibodies (  40, 41  ), 
whereas changes in the length of homopolymeric tracts in the 
  porA   promoter or coding sequences can aff  ect transcription 
or translation, respectively (  42  ). 
    Figure 7.         Enhanced activity of the AP on sensitive strains.   Binding of C3 (A and C) and MAC (B and D) to bacteria detected by FACS analysis after 
incubation in immune human serum pooled from 10 donors. Results are shown as the MFI (calculated as geometric mean multiplied by the percentage of 
gated cells), and the error bars show the SEM. In B and D, strains were incubated with serum in the presence of magnesium and EGTA to block the CP and 
LP (-CP/LP). Error bars show the SEM of assays performed in triplicate. There was signifi  cantly less binding of complement factors to R3 and S3::R com-
pared with S3. P   <   0.01 in all assays with the Student  ’  s   t   test.   JEM VOL. 205, June 9, 2008 
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Second, the insertion sequence may have only recently inserted 
into the IGR, and this change might not have yet had the 
opportunity to spread among disease isolates. Finally, although 
increased expression of the capsule might be benefi  cial for 
survival in serum, there may be trade-off  s in which the inser-
tion of IS  1301   in the IGR is detrimental for the bacterium at 
other stages of its lifecycle. Sialic acid is synthesized from 
  N  -acetyl mannosamine and phosphoenol pyruvate (  53  ). The 
latter is part of intermediary carbon metabolism, and chan-
neling of phosphoenol pyruvate into capsule biosynthesis may 
lead to a reduced growth in certain environments; we have 
been unable to demonstrate a growth defect for the R strains 
in complete or defi  ned media. Furthermore, the presence 
of capsule is known to inhibit pilus-mediated adhesion to 
human epithelial cells (  54, 55  ), and a minor impairment of 
this critical step during colonization may provide suffi   cient 
selective pressure to prevent the widespread emergence of 
these strains with increased resistance against complement-
mediated killing. 
  Many mechanisms can generate genetic diversity among 
meningococcal isolates. In contrast to other changes, inser-
tion of IS  1301   in the   siaA  -  ctrA   IGR is a single genetic change 
that can provide strains with a generic mechanism for avoid-
ing complement-mediated lysis, regardless of the nature of 
the target antigen. This is indicated by the increased resis-
tance of the strains against killing mediated by the     -Por 
mAb, mouse sera raised against whole bacteria, and human 
sera from vaccinees. However, it is not clear whether strains 
with this change will compromise the effi   cacy of meningo-
coccal vaccines; polysaccharide vaccines have been available 
against MenC for   >  30 yr with no reports of emerging re-
sistant strains to date. Despite this, studies are needed to ex-
amine the distribution and spread of strains with IS  1301   in 
the   siaA-ctrA   IGR during meningococcal carriage and dis-
ease, and before and after the implementation of immuni-
zation programs. 
  MATERIALS AND METHODS 
  Bacterial strains and growth.       N. meningitidis   isolates used in this study are 
shown in   Table II  , and were characterized by their expression of surface an-
tigens,   fumC   sequencing, and multilocus sequencing typing (  20  ).   Meningo-
coccal strains were grown on brain heart infusion (BHI) medium with 5% 
virulence determinants, including capsule. The mechanisms 
by which IS  1301   increases mRNA levels of both   siaA   and 
  ctrA   are likely to be complex, as these genes are divergently 
transcribed from overlapping promoters (  26, 27  ). Our pre-
liminary data indicate that IS  1301   harbors promoter elements 
(unpublished data), although this does not exclude the possi-
bility that the insertion displaces negatively acting regulators, as 
described previously (  44  ). 
  The cryo-TEM technique we used (  49  ) permitted visual-
ization of bacteria without sectioning or contrast enhance-
ment; ferritin was used to stain bacteria through its charge-based 
attraction to anionic capsules (  31  ). The specifi  city of this 
method was demonstrated by the lack of staining of the cap-
sule-negative mutant (  Fig. 6  ). Strains R3 and S3::R produced 
more capsule compared with S3, consistent with FACS results 
(  Fig. 5  ). Rather than being evenly distributed over the entire 
surface of the bacterium, the increased capsule in the R strains 
occasionally formed irregular extracellular aggregates, which 
might serve to divert bactericidal antibodies and complement 
factors away from the bacterial outer membrane. However, 
this appearance may be an artifact of TEM, and further studies 
are underway to measure the rates of capsule shedding by 
the strains. 
  Serogroups of   N. meningitidis   that express sialic acid  –  con-
taining capsules present a signifi  cant threat to human health (  13  ). 
There are no broadly eff  ective, licensed vaccines against sero-
group B   N. meningitidis  , which remains the leading cause of 
disease in North America and Europe. Serogroup W135 strains 
have caused large outbreaks of meningococcal disease in sub-
Saharan Africa and the global spread of infection from the Hajj 
pilgrimage in 2000 (  11  ), whereas serogroup Y infections have 
emerged as a major problem in North America (  50  ). The   sia-ctr   
IGR is present in all meningococcal serogroups that produce 
sialic acid capsules (  23  ). Therefore, strains belonging to these 
serogroups could become capsule hyperproducers after acqui-
sition of IS  1301   in the IGR by transformation. 
  Typing methods for the meningococcus do not routinely 
assess sensitivity to bactericidal antibodies, as this is a labori-
ous task that is diffi   cult to standardize (  51  ). However, this in-
formation is vital for understanding the potential range of effi   cacy 
of novel vaccines, virulence mechanisms used by strains, and 
the molecular basis of the emergence of pathogenic clones. 
Clearly, the presence of IS  1301   in the   sia-ctr   IGR can be de-
tected by PCR and could be used to screen for strains with 
increased resistance, which, as hyperproducers of capsular 
polysaccharide, could be valuable for vaccine manufacturing. 
Furthermore, this genetic change might explain some of the 
diff  erent behaviors of isolates in serum assays, as well as the 
variations obtained between laboratories. 
  From a collection of 109 strains from Spain, we identifi  ed 
three isolates with IS  1301   in the   siaA  -  ctrA   IGR. Although 
this insertion confers a marked survival advantage to strains 
in the presence of immune sera, there are several potential rea-
sons why this change is not more widespread among isolates. 
First, it is possible that these strains may be eff  ectively cleared 
by other immune mechanisms, such as opsonphagocytosis (  52  ). 
    Table II.        Isolates used in this study 
Strain Serogroup Type ST Immunotype
C11 C 16:P1.7 345 1
S1 (13213) C 2a:P1.5 11 2, 5
S2 (14624) C 2a:P1.5 11 2, 5
S3 (14709) C 2a:P1.5 11 n.k.
S4 (14715) C 2a:P1.5 11 2, 5
S5 (14840) C 2a:P1.5 11 2, 5
R1 (14654) C 2a:P1.5 11 2, 5
R2 (16015) C 2a:P1.5 11 n.k.
R3 (15967) C 2a:P1.5 11 n.k.
Reference laboratory numbers are shown in parentheses. n.k., not known.1432 INCREASED COMPLEMENT RESISTANCE IN   N. MENINGITIDIS   | Uria et al.
calculated as the MFI (calculated as geometric mean multiplied by the 
percentage of positive cells). 
  To assess the binding of complement factors, bacteria were grown and 
fi  xed to midlogarithmic phase in liquid culture, and 2   ×   10  7   cells were incu-
bated with pooled immune sera from 10 vaccinees (1:5 dilution) for 30 min 
at 37  °  C, washed twice, and resuspended in PBS-T with FITC-conjugated 
polyclonal goat anti  –  human C3 (1:300 dilution; MP Biomedicals), or a 
polyclonal rabbit anti  –  human C5b-9 (1:200 dilution; EMD), which was de-
tected with goat anti  –  rabbit IgG Alexa Fluor 488 (1:200; Invitrogen). The 
activity of the CP and LP was inhibited in sera in the presence of 2 mM 
MgCl  2   and 2 mM EGTA (  37  ). 
  SBA and serum assays.     SBA titers were measured according to standard 
protocols from the Centers for Disease Control (  57  ). In brief,   N. meningitidis   
was grown on solid media overnight and subcultured on plates for 4  –  5 h. 
Bacteria were harvested and resuspended in SBA buff  er, and 10  4   bacteria 
were incubated for 1 h with serial dilutions of heat-inactivated (56  °  C for 
30 min) vaccinees  ’   serum in the presence of baby rabbit complement 
(Pelfreeze). The antiserosubtyping P1.5 mAb (hybridoma 4023; National 
Institute for Biological Standards and Control) was used in SBA assays to de-
tect killing mediated against PorA. Control assays were performed without 
serum or without complement. The proportion of bacteria surviving was 
determined by plating to solid media. Assays were performed on four inde-
pendent occasions, and results were given as the inverse of the highest di-
lution of serum that gave   >  50% killing of the input. SBA titers were also 
determined with human complement obtained from a patient with agam-
maglobulinaemia before he had received replacement therapy. 
  For serum assays, bacteria were grown in liquid media to midlogarith-
mic phase in liquid culture, 10  4   CFU was incubated with serial dilutions of 
pooled human immune serum (from 10 donors) for 1 h, and the proportion 
of bacteria surviving was determined (  56  ). Control assays included sera inac-
tivated by heating at 56  °  C for 30 min; signifi  cant diff  erences were examined 
with the Student  ’  s   t   test. 
  Electron microscopy.     Bacteria were grown overnight on solid media, 
harvested, and resuspended in PBS prewarmed to 37  °  C. An aliquot of the 
suspension was mixed with prewarmed, cationized ferritin (F7879; Sigma-
Aldrich) to a fi  nal concentration of 0.5 mg/ml. Plasma-cleaned hydro-
philic Quantifoil TEM grids (S143-8; Agar Scientifi  c Ltd.) were fl  oated on 
the sample and incubated for 30 min at 37  °  C in the presence of 5% CO  2  . 
Excess fl  uid was removed by wicking, and the samples were vitrifi  ed by 
plunging into liquid ethane (CPC; Leica) before being transferred into a 
liquid N  2    –  cooled specimen holder (model 626; Gatan). A TEM (JEM-
2100; JEOL) operating at 200 keV was used to record images on a 4,048   ×   
4,048  –  pixel charge-coupled device camera (Gatan). The cumulative elec-
tron dose was maintained at   <  55 electrons/  Å    2  . The microscope was cali-
brated against a carbon waffl   e (Grating Replica, Waffl   e, 2160 lines/mm; 
Ted Pella Inc.). 
  Capsule purifi  cation and NMR analysis.     Capsules were purifi  ed as de-
scribed previously (  18  ). In brief, bacteria were grown in 200 ml of BHI me-
dia overnight, and cetavlon (Sigma-Aldrich) was added to a fi  nal concentration 
of 1% to lyse the bacteria and precipitate the polysaccharide. The precipitates 
were collected by centrifugation and resuspended in distilled water, and 
CaCl  2   was added to separate the polysaccharide from the detergent. Nucleic 
acids in the solution were removed by ethanol precipitation (25% vol/vol). 
The capsular polysaccharide in the supernatant was precipitated by ethanol at 
a fi  nal concentration of 80% (vol/vol); traces of cetavlon and CaCl  2   were re-
moved by washing with 100% ethanol. NMR spectra (500MHz at 60  °  C in 
D  2  O) were recorded on a spectrometer (INOVA 500; Varian) using pulse 
sequences provided by the manufacturer (  29, 58  ). 
  Immunization.     Groups of 8-wk-old BABL/c mice were immunized with 
0.1 ml of MCC vaccine (Wyeth Vaccines) by the subcutaneous route on 
days 0, 14, and 21. Serum was obtained from immunized animals on day 28. 
Levanthal  ’  s supplement.   Escherichia coli   was propagated on Luria-Bertani 
media with antibiotics as required. 
  Molecular methods.     Genomic and plasmid DNA were extracted by stan-
dard methods, and PCRs were performed with Taq polymerase (Sigma-
Aldrich). The oligonucleotides used in this study are shown in Table S2 
(available at http://www.jem.org/cgi/content/full/jem.20072577/DC1). 
For RNA isolation, bacteria were grown in a 10-ml volume in liquid BHI 
media with gentle agitation to midlogarithmic phase with an OD A  600   of 
    0.6. Cells were harvested by centrifugation at 4,000   g  , and RNA was ex-
tracted with the RNeasy mini kit (QIAGEN). Genomic DNA was removed 
by treatment with DNase (QIAGEN). 500 ng RNA was reverse transcribed 
to cDNA using the SuperScript III First-Strand Synthesis kit (Invitrogen). 
Transcript levels were measured by qrtRT-PCR) using SensiMix with 
SYBR green detection (Quantace) on a thermal cycler (Rotor-Gene 3000; 
Corbett Research). Results for the transcription of   siaA   and   ctrA   were nor-
malized with levels for the housekeeping gene   gdh  . The following primers 
were used to monitor transcript levels: NG770 and NG771 to generate a 
221-bp   siaA   product; NG772 and NG773 to generate a 194-bp   ctrA   prod-
uct; and NG886 and NG887 to generate a 235-bp   gdh   product. Data were 
analyzed using the comparative quantitation method by Rotor-Gene soft-
ware (version 6.0; Corbett Research). Controls included reactions with no 
template and samples of RNA that had not been treated with RT. qrtRT-
PCR was performed in triplicate on cDNA samples derived from three 
independent cultures. 
  Strains lacking   lst   and   siaD   have been described previously (  56  ). For in-
activation of   oatC  , a 2.2-kb fragment, including this gene, was amplifi  ed 
using primers NG541 and NG542. The product was ligated into pCR 2.1 
Topo (Invitrogen), and the gene encoding kanamycin resistance was re-
moved from the vector by   Sph  I digestion and self-ligation. The resulting 
plasmid was subjected to in vitro mutagenesis with EZ-Tn5 (EPICENTRE), 
and the transposon insertion sites were mapped by sequencing. One plasmid, 
containing Tn5 at nucleotide 1,084 of the   oatC   open reading frame, was used 
for transformation. A similar strategy was used to mark IS  1301   in the   siaA  -
  ctrA   IGR before transfer into S3; a 1.6-kb fragment, including the IGR with 
IS  1301   and part of   siaA   and   ctrA  , was amplifi  ed from strain R3 with primers 
NG679 and NG687, ligated into pCR 2.1 Topo, and the kanamycin-sensitive 
derivative was subjected to in vitro mutagenesis. Primers NG732 and NG733 
were used to screen isolates for the presence of IS  1301.   Transformants were 
verifi  ed by PCR and Southern analysis. 
  Western and FACS analyses.     For LPS analysis, whole-cell extracts were 
prepared in loading buff  er, treated with proteinase K (QIAGEN), and sub-
jected to Tricine SDS-PAGE analysis. LPS was subjected to Western analysis 
using mAb 3F11, which detects unsialylated LPS (provided by M. Apicella, 
University of Iowa, Iowa City, Iowa), as described previously (  56  ). Antipep-
tide antibodies were generated by immunizing rabbits with a SiaA peptide 
(DVGTRQNNRHMGKSI) on three occasions, and the sera was affi   nity 
purifi  ed and used at a fi  nal dilution of 1:500. The anti-RecA antibody (Bio-
Academia) was used at a 1:10,000 concentration. The secondary antibody was 
horseradish peroxidase  –  conjugated goat anti  –  rabbit Ig antibodies (1:10,000 
concentration; Dako). 
  For FACS analysis, strains were grown to midlogarithmic phase in 
liquid media as in the previous section, collected by centrifugation, fi  xed in 
3% paraformaldehyde for at least 1 h, and washed three times with PBS. 
Next, bacteria (2   ×   10  7   cells) were incubated with a primary antibody at the 
following dilutions: mAb 1125 (provided by H. Claus, University of W  ü  rzburg, 
W  ü  rzburg, Germany) at a 1:500 dilution; and anticapsular sera at a 1:10 di-
lution in PBS for 30 min at 37  °  C. The cells were then washed twice, re-
suspended in PBS/0.1% Tween 20 (PBS-T) containing an FITC-conjugated 
donkey anti  –  mouse polyclonal antibody (1:200 dilution; Jackson Immuno-
Research Laboratories), and incubated for 30 min on ice. After washing 
with PBS-T, fl  uorescence was measured using an analyzer (FACSCalibur; 
Becton Dickson), recording at least 10  4   events. The gate was set at     2% of 
cells after incubation with PBS without a primary antibody. Results were JEM VOL. 205, June 9, 2008 
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media and harvested to PBS, and the number of CFU was determined by 
measuring the OD A  260   of a lysate of cells in 0.1 M NaOH/1% SDS (  56  ). All 
procedures were approved by a Home Offi   ce license. 
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(Table S1), as well as primers and isolates used in this study (Table S2). 
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